Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Memorial Sloan Kettering Cancer Center
With
National Cancer Institute (NCI)
National Institutes of Health (NIH)
Rockefeller University
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of metastatic melanoma, AJCC stage III or IV, with histologic confirmation by Dept. of Pathology at MSKCC.
Patients must be HLA-A\*0201 positive.
Expected survival of greater than 3 months.
Karnofsky performance status 70 or better.
Patients may not have received chemotherapy, immunotherapy, or radiation within approximately 4 weeks (approximately 6 weeks for nitrosoureas or mitomycin) before participation in this protocol.
Patients should not be receiving immune modifying pharmacologics (e.g., interferon) for approximately 2-4 weeks before enrollment.
You may not be if
Pregnant (clinically documented or positive pregnancy test within approximately 2 wks of study entry) or lactating women, because immunization will include differentiation antigens shared by melanoma tumors and melanocytes, and immune responses to these differentiation antigens could have unknown developmental sequelae to a fetus or infant.
Pregnancy tests are not required for post-menopausal women, and post-menopausal status by patient report should be documented accordingly.
Patients requiring systemic corticosteroids or comparable exogenous immunosuppressive agent(s) (no exclusion for use of NSAIDs)
Patients who have a known immunodeficiency (e.g., infection with HTLV-1,2, HIV-1,2; etc.) because of the T cell defects that would alter their responses and the investigators' ability to assess their outcomes accurately.
Patients with preexisting retinal or choroidal eye disease.
Patients with coexisting autoimmune diseases, except vitiligo.
Patients with significantly impaired hematologic, hepatic, or renal function, e.g., ANC \<1000, hgb \< 8.0 g/dl, plts \< 50,000/ul, AST \>3x ULN, creatinine \>2.0 or Cl creat \<30ml/min, all assessed within approximately two weeks of study entry.
Patients with serious coexisting medical illness.
Patients with organ allografts.
Patients who are s/p splenectomy or s/p splenic irradiation.
Patients with active brain metastases.
Patients with organic brain syndrome or psychologic impairment that would preclude participation and compliance with this protocol.
Clareo Health | Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy
